Hyrimoz 40mg/0.8ml Injection (Adalimumab)

Recommended Dosage of Hyrimoz 40mg Injection

The recommended dosage of Hyrimoz 40 mg injection varies based on the specific condition being treated. Below are the guidelines for different indications:

Adult Dosage

Rheumatoid Arthritis

Initial Dose: 40 mg every other week.
Alternative: If not taking methotrexate, the dose may be adjusted to 40 mg every week or 80 mg every other week based on response.

Psoriatic Arthritis

Dosage: 40 mg every other week.
Ankylosing Spondylitis
Dosage: 40 mg every other week.

Crohn’s Disease

Induction: 160 mg at week 0 (can be given as four 40 mg injections on one day or two injections per day over two days), followed by 80 mg at week 2 (two 40 mg injections in one day).
Maintenance: 40 mg every other week.

Ulcerative Colitis

Induction: 160 mg at week 0 (four 40 mg injections on one day or two injections per day over two days), followed by 80 mg at week 2 (two 40 mg injections in one day).
Maintenance: 40 mg every other week.

Hidradenitis Suppurativa

Induction: 160 mg initially (four 40 mg injections on Day 1 or two injections on two consecutive days), followed by 80 mg two weeks later (two 40 mg injections on the same day).
Maintenance: 40 mg every week or 80 mg every other week starting two weeks after the last dose.

Plaque Psoriasis

Induction: 80 mg initially, followed by 40 mg starting one week later, administered every other week.

Warnings and Precautions of Hyrimoz 40mg Injection

Hyrimoz 40 mg injection carries several warnings and precautions that patients should be aware of before and during treatment. Here are the key considerations:

Warnings

Infections: Hyrimoz may increase the risk of serious infections, including tuberculosis (TB) and other opportunistic infections. Patients should be screened for TB before starting treatment, and any signs of infection should be reported to a healthcare provider immediately.

Malignancies: There is an increased risk of certain cancers in patients treated with TNF blockers like Hyrimoz. This includes lymphomas and other malignancies. Patients with a history of malignancy should discuss this with their doctor.

Heart Failure: Hyrimoz can exacerbate heart failure in patients with existing heart conditions. Patients should be monitored for signs of heart failure, and treatment should be discontinued if new or worsening heart failure symptoms occur.

Demyelinating Disorders: Patients with a history of demyelinating diseases (e.g., multiple sclerosis) should use Hyrimoz cautiously, as it may worsen these conditions.

Hepatitis B Reactivation: Patients with a history of hepatitis B virus infection are at risk for reactivation of the virus during treatment. Screening for hepatitis B should be performed before starting therapy.

Precautions

Vaccinations: Patients should consult their healthcare provider before receiving any vaccinations, as live vaccines should generally be avoided during treatment with Hyrimoz. It is advisable to be up to date with all vaccinations before starting therapy.

Pregnancy and Breastfeeding: The effects of Hyrimoz during pregnancy are not fully understood. Women should inform their doctor if they are pregnant, plan to become pregnant, or are breastfeeding. The decision to continue breastfeeding during treatment should be discussed with a healthcare provider.

Other Medications: Inform your doctor about all medications you are taking, including over-the-counter drugs and supplements, as Hyrimoz may interact with other treatments.

Monitoring: Regular monitoring by a healthcare provider is essential to assess the effectiveness of the treatment and to check for any adverse effects, especially during the initial months of therapy.

Long-term Treatment: The benefits and risks of continued long-term treatment with Hyrimoz should be periodically evaluated, especially in patients who do not show improvement within a specified time frame.

Possible Side Effects of Hyrimoz 40mg Injection

Hyrimoz 40 mg injection may cause a range of side effects, some of which can be serious. Here are the possible side effects associated with this medication:

Common Side Effects

Injection Site Reactions: These may include pain, redness, swelling, itching, or bruising at the injection site.

Upper Respiratory Infections: Such as sinusitis and other respiratory infections.

Headaches: A frequent complaint among users.

Rash: Skin reactions can occur, including general rashes.

Serious Side Effects

Serious Infections: Hyrimoz can increase the risk of serious infections, including tuberculosis (TB), which may manifest as persistent cough, weight loss, fever, and fatigue. Patients should be monitored for signs of infection.

Hepatitis B Reactivation: In individuals who are carriers of the hepatitis B virus, Hyrimoz can lead to reactivation of the virus, which may result in severe liver complications. Symptoms include fatigue, dark urine, yellowing of the skin or eyes, and abdominal pain.

Allergic Reactions: Serious allergic reactions can occur, presenting as hives, swelling of the face, lips, or tongue, and difficulty breathing. Immediate medical attention is required if these symptoms develop.

Nervous System Problems: Rare cases of demyelinating diseases (such as multiple sclerosis) have been reported. Symptoms may include numbness, tingling, vision problems, and weakness in limbs.

Blood Disorders: There may be a decrease in blood cells, leading to symptoms such as persistent fever, easy bruising, or unusual bleeding.

Heart Failure: New or worsening heart failure can occur, with symptoms including shortness of breath, swelling in the ankles or feet, and sudden weight gain.

Autoimmune Reactions: Some patients may develop a lupus-like syndrome, characterized by joint pain, rash, and chest discomfort.

Liver Problems: Symptoms may include fatigue, yellowing of the skin or eyes, and abdominal pain, which can lead to severe liver failure.